AdAlta Limited (ASX:1AD)
Australia
· Delayed Price · Currency is AUD 0.0040
0.00 (0.00%)
Mar 10, 2026, 1:36 PM AEST
AdAlta Company Description
AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia.
Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration.
It has discovered WD-34 for the multiple malaria species, Babesia, and Toxoplasma in collaboration with La Trobe University.
The company was incorporated in 2006 and is based in Camberwell, Australia.
AdAlta Limited
| Country | Australia |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Timothy Oldham |
Contact Details
Address: 697 Burke Road Camberwell, VIC 3124 Australia | |
| Phone | 61 3 9479 5159 |
| Website | adalta.com.au |
Stock Details
| Ticker Symbol | 1AD |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000001AD2 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Timothy Charles Oldham B.Sc., BSc(Hons), L.L.B., LLB(Hons), Ph.D. | Chief Executive Officer, MD and Director |
| Angus Tester Ph.D. | Senior Director of Operations |
| Prof. Michael Foley Ph.D. | Founding Chief Scientist |
| Dr. Andrew Peter O'Brien MBA., Ph.D. | Head of Corporate Development |
| Janette Dixon | Head of Business Development |
| Dr. Kevin Patrick Lynch FFPM, M.D., MBBS | Consultant Chief Medical Officer of Oncology |
| Cameron Peter Jones C.A. | Company Secretary |